Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly

The research with new agents is particularly active in acute myeloid leukemia (AML) and different studies suggest a potential utility of hypomethylating agents (HMA) in this disease. In this article, we critically appraise some recent clinical data reported on the use of HMA for the treatment of AML in older patient.